nedosiran

10/01/2021 - "Nedosiran represents a novel and impactful potential therapeutic for PH1 patients with end-stage renal disease."

06/05/2023 - "Correction to: Nedosiran in primary hyperoxaluria subtype 3: results from a phase I, single-dose study (PHYOX4)."
04/28/2023 - "Nedosiran in primary hyperoxaluria subtype 3: results from a phase I, single-dose study (PHYOX4)."
01/01/2022 - "Safety, pharmacodynamics, and exposure-response modeling results from a first-in-human phase 1 study of nedosiran (PHYOX1) in primary hyperoxaluria."
12/01/2023 - "Nedosiran is an investigational RNA-interference therapeutic in development for primary hyperoxaluria (PH). "
07/01/2022 - "Unfortunately, despite initial hopes that nedosiran may also be a treatment option for primary hyperoxaluria types 2 and 3, initial data suggest otherwise. "

01/01/2023 - "PHYOX2: a pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2."
01/01/2023 - "A Case Report of Kidney-Only Transplantation in Primary Hyperoxaluria Type 1: A Novel Approach with the Use of Nedosiran."
07/01/2022 - "Lumasiran was recently approved in the treatment of primary hyperoxaluria type 1 and nedosiran is in the approval process. "

01/01/2023 - "In the nedosiran arm, the incidence of injection-site reactions was 9% (all mild and self-limiting). "
11/11/2022 - "In addition to common injection site reactions that resolved spontaneously, no severe nedosiran treatment-associated adverse events were reported. "

12/01/2023 - "Because nedosiran undergoes renal clearance, we assessed its pharmacokinetic profile in non-PH participants with normal kidney function and Stages 4/5 chronic kidney disease (CKD), the latter with/without dialysis. "
12/01/2023 - "Safety, Pharmacokinetics, and Exposure-Response Modeling of Nedosiran in Participants With Severe Chronic Kidney Disease."